logo
CNBC Daily Open: The U.S. economy is not built on rock and roll

CNBC Daily Open: The U.S. economy is not built on rock and roll

CNBC18-07-2025
Despite the noise around tariffs and inflation fears, the U.S. economy seems to be holding its ground — for now. June retail sales came in stronger than expected, and weekly jobless claims dropped below forecasts.
Add to that a solid start to earnings season, and you've got a recipe for record highs: both the S&P 500 and Nasdaq notched fresh peaks.
So, is the economy truly resilient in the face of the Trump administration's shifting trade winds? Or are we simply in the eye of the storm, with August 1 — the Trump tariff deadline — looming on the horizon?
Remember, economic data is always a step behind. The real impact of tariffs may not show up for months, especially if businesses and consumers are stockpiling ahead of time and foreign exporters are cutting their prices.
Even when the new tariffs hit, the effects might be muted at first as inventories clear.Still, for now, investors can take comfort in the fact that markets are being lifted by fundamentals — not just fear or speculation.
And yes, to borrow a line from Starship: the U.S. economy is still built on rock-solid data… not on rock and roll.
Netflix posts earnings beat. Revenue for the streaming giant grew 16% during the second quarter of 2025. The company also updated its full-year revenue forecast, noting that it expects revenue to be between $44.8 billion and $45.2 billion, up from a range of $43.5 billion to $44.5 billion, reflecting the weakening of the U.S. dollar, "healthy" member growth and ad sales, it said in a statement.
S&P and Nasdaq storm to new records. U.S. stocks climbed Thursday due to solid earnings and economic data, with the S&P 500 up 0.54% for a record close of 6,297.36 — its ninth this year. The tech-heavy Nasdaq Composite advanced 0.75% for its tenth record close of 2025, ending at 20,885.65. The pan-European Stoxx 600 gained 0.96% after a raft of earnings reports.
Trump takes aim at solar and wind projects. U.S. Interior Secretary Doug Burgum will now have the final say on whether those projects can proceed on U.S.-owned lands, as a way of "levelling the playing field" for coal and natural gas "after years of assault" by Biden administration, according to an Interior Department's internal memo Thursday.
Layoffs at Amazon continue. The company confirmed layoffs in its cloud computing division Thursday. The company declined to say which units within Amazon Web Services were impacted, or how many employees will be let go as a result of the job cuts, but AWS' training and certification unit was one of the groups to see cuts, according to a memo viewed by CNBC.
[PRO] The U.S. consumer pushes back on recession fears. U.S. consumers appear to prove economic pessimists wrong this summer as they flex their spending muscle, according to June's retail sales report. But some alternative data suggests that the consumer is hanging in there.
AI-generated music is going viral. Should the music industry be worried?
With more than 1 million monthly listeners on Spotify, psychedelic rock band The Velvet Sundown is raking in thousands of dollars.
However, the "band" was recently confirmed to primarily be the work of generative artificial intelligence 一 something that had been heavily suspected and has the music industry asking itself questions.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says
Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says

Yahoo

time14 minutes ago

  • Yahoo

Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says

By Andrew Silver HANGZHOU (Reuters) -China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for American patients, the drugmaker's chief executive told Reuters. Overweight patients treated with Sciwind's ecnoglutide drug lost an average of 10% to 15% of their body weight, roughly in line with results from Novo Nordisk's top-selling obesity treatment Wegovy, according to a late-stage study published in medical journal The Lancet Diabetes & Endocrinology in June. 'We also hope we are able to successfully license out, and they will apply for approval in the U.S.,' Sciwind Biosciences CEO Pan Hai said, declining to identify the firm or disclose financial terms under discussion. Reuters is the first to report on the potential U.S. licensing deal. Pan said its potential partner hoped to gain U.S. marketing approval to prescribe ecnoglutide for multiple medical conditions and would carry out further clinical development. The talks are not yet at the stage of discussing a detailed contract, he added. Sciwind is hoping the partner could use clinical data accumulated in China and Australia to accelerate the development. Pan expects it would take at least three years for a U.S. partner to bring Sciwind's drug to market in the United States, and said the FDA might require a bridging study to compare ecnoglutide's pharmacokinetics - how it moves through the body - among different patient populations. Ecnoglutide is administered as a once-weekly injection. It belongs to a class of drugs called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. Novo's Wegovy and Eli Lilly and Co's Zepbound lead the U.S. market for weight-loss drugs, but their relatively high prices leave room for new competitors to offer cheaper alternatives. Sciwind has applied to sell ecnoglutide in China for weight management and the treatment of type II diabetes. Other approved weight loss medicines in China also include drugs from Novo, Lilly and other drugmakers. Pan said he could not give an estimated time of approval. The company is also in talks to license the drug to partners for other markets, including in Latin America and the Middle East. Pricing in China would be in line with other approved competitors, Pan said, adding the company would not engage in a "price war" there. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

What You Need to Know Ahead of Ross Stores' Earnings Release
What You Need to Know Ahead of Ross Stores' Earnings Release

Yahoo

time14 minutes ago

  • Yahoo

What You Need to Know Ahead of Ross Stores' Earnings Release

With a market cap of $42.8 billion, Ross Stores, Inc. (ROST) operates off-price retail apparel and home fashion stores under the Ross Dress for Less and dd's DISCOUNTS brands in the United States. Headquartered in Dublin, California, the company offers apparel, accessories, footwear, and home fashions products. ROST is expected to report its Q2 earnings on Thursday, Aug. 28. Ahead of the event, analysts expect ROST to report a profit of $1.53 per share, down 3.8% from a profit of $1.59 per share reported in the year-ago quarter. It has exceeded analysts' earnings estimates in each of the past four quarters, which is notable. More News from Barchart 2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025 UnitedHealth Stock Spirals Lower Again. Don't Buy the Dip. Auto Revenue Keeps Plunging at Tesla. Should You Buy the TSLA Stock Dip or Run Far Away? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For the current year, analysts expect ROST to report EPS of $6.23, down 1.4% from $6.32 in fiscal 2024. However, its EPS is likely to rise 9% year over year to $6.79 in FY2026. Over the past year, ROST shares surged 4%, underperforming the S&P 500 Index's ($SPX) 17.3% gains and the Consumer Discretionary Select Sector SPDR Fund's (XLY) 22.9% returns over the same time frame. On Jul. 2, shares of Ross Stores climbed more than 1% after Jefferies Financial Group Inc. (JEF) upgraded the stock from a 'Hold' to a 'Buy' rating. The firm also raised its price target to $150, citing improved traffic trends, solid inventory management, and a favorable off-price retail environment as key catalysts for potential upside in the stock. The consensus opinion on ROST stock is highly upbeat, with an overall 'Strong Buy' rating. Out of the 19 analysts covering the stock, 15 recommend a 'Strong Buy' and four recommend a 'Hold.' Its mean price target of $154.53 indicates a robust 11.1% upside potential from current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Dollar Tree Earnings Preview: What to Expect
Dollar Tree Earnings Preview: What to Expect

Yahoo

time14 minutes ago

  • Yahoo

Dollar Tree Earnings Preview: What to Expect

Dollar Tree, Inc. (DLTR) is a major U.S. discount retailer headquartered in Virginia, operating over 9,000 stores under the Dollar Tree and Dollar Tree Canada brands. With a market cap of $24 billion, the company offers a wide range of consumables, seasonal goods, and general merchandise through its physical locations and bulk e-commerce platform, supported by a nationwide logistics network. The company is expected to announce its fiscal Q2 2025 earnings results on Wednesday, Sept. 3. Ahead of this event, analysts expect the company to report an adjusted EPS of $0.36, down 46.3% from $0.67 in the year-ago quarter. It has surpassed Wall Street's earnings estimates in two of the last four quarters while missing on two other occasions. More News from Barchart 2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025 UnitedHealth Stock Spirals Lower Again. Don't Buy the Dip. Auto Revenue Keeps Plunging at Tesla. Should You Buy the TSLA Stock Dip or Run Far Away? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For fiscal 2025, analysts expect the discount store chain to report an adjusted EPS of $5.43, up 6.5% from $5.10 in fiscal 2024. In addition, adjusted EPS is anticipated to grow 15.1% year-over-year to $6.25 in fiscal 2026. DLTR shares have climbed 10.2% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 17.3% gain but surpassing the Consumer Staples Select Sector SPDR Fund's (XLP) 4.6% return over the same period. On July 21, shares of Dollar Tree gained more than 2% following an upgrade from Barclays plc (BCS), which raised its rating on the stock to 'Overweight' from 'Equal Weight.' The firm also lifted its price target to $120, citing improved fundamentals and growing confidence in the company's turnaround strategy. Barclays highlighted Dollar Tree's focus on reaccelerating growth through store remodels, pricing flexibility with its Dollar Tree Plus format, and the recent divestiture of its underperforming Family Dollar segment as key catalysts. The upgrade reflects optimism around the retailer's potential to expand margins, drive stronger traffic, and enhance shareholder value in the coming quarters. Analysts' consensus view on Dollar Tree's stock is cautiously optimistic, with a "Moderate Buy" rating overall. Among 23 analysts covering the stock, eight recommend "Strong Buy," 13 suggest "Hold," one gives "Moderate Sell," and one 'Strong Sell.' DLTR currently trades above its average analyst price target of $99.28. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store